版本:
中国

BRIEF-Sangamo receives fast track designation from FDA for SB-525

May 16 Pfizer Inc-

* Sangamo receives fast track designation from the FDA for sb-525 investigational hemophilia a gene therapy

* Sangamo Therapeutics Inc says data from phase 1/2 clinical trial evaluating sb-525 in adults with hemophilia a expected in late 2017 or early 2018 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐